Literature DB >> 19392622

Community-associated strains of methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus in indigenous Northern Australia: epidemiology and outcomes.

Steven Y C Tong1, Emma J Bishop, Rachael A Lilliebridge, Allen C Cheng, Zornitsa Spasova-Penkova, Deborah C Holt, Philip M Giffard, Malcolm I McDonald, Bart J Currie, Craig S Boutlis.   

Abstract

BACKGROUND: Some strains of non-multidrug-resistant, methicillin-resistant Staphylococcus aureus (nmMRSA) in Australia are likely to have emerged from strains of methicillin-susceptible S. aureus (MSSA) in remote Aboriginal communities.
OBJECTIVE: To describe the clinical epidemiology of infection due to community-associated MRSA strains in an Australian tropical hospital setting with a significant Aboriginal population and to compare infections caused by community-associated strains of MRSA, health-care-associated strains of MRSA, and MSSA strains with respect to demographic risk factors and clinical outcomes. Methods. We queried the microbiology database for the Top End of the Northern Territory, Australia, to determine population incidences for S. aureus infection and conducted a prospective matched case-control study to compare infection due to nmMRSA, MSSA, or multidrug-resistant MRSA at the Royal Darwin Hospital.
RESULTS: The annual incidence of S. aureus bacteremia was 65 cases per 100,000 population, but in the Aboriginal population the incidence was 172 cases per 100,000 population (odds ratio [OR] compared with non-Aboriginal population, 5.8 [95% confidence interval {CI}, 3.8-8.9). Female sex (adjusted OR [aOR], 1.5 [95% CI, 1.1-2.0) and remote residence (aOR, 1.8 [95% CI, 1.2-2.5]) were associated with the isolation of nmMRSA rather than MSSA, but disease spectrum and outcomes were similar. Among those from whom nmMRSA was isolated, Aboriginal patients were younger (aOR for each additional year, 0.94 [95% CI, 0.92-0.96]), more likely to be female (aOR, 3.8 [95% CI, 1.7-8.5]), and more likely to reside in a remote community (aOR, 29 [95% CI, 8.9-94]) than non-Aboriginal patients. The presence of Panton-Valentine leukocidin in nmMRSA was associated with double the odds of sepsis (aOR, 2.2 [95% CI, 1.1-4.6]).
CONCLUSIONS: The association of nmMRSA infection with female sex and remote residence supports the hypothesis that nmMRSA arose from MSSA strains in remote Aboriginal communities where staphylococcal disease is highly prevalent. The similar clinical spectrum and outcomes for nmMRSA infection and MSSA infection suggest that virulence is not correlated with resistance phenotype.

Entities:  

Mesh:

Year:  2009        PMID: 19392622     DOI: 10.1086/598218

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  48 in total

Review 1.  Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?

Authors:  Steven Y C Tong; Luke F Chen; Vance G Fowler
Journal:  Semin Immunopathol       Date:  2011-12-11       Impact factor: 9.623

2.  Impact of results of a rapid Staphylococcus aureus diagnostic test on prescribing of antibiotics for patients with clustered gram-positive cocci in blood cultures.

Authors:  Jane Davies; Claire L Gordon; Steven Y C Tong; Robert W Baird; Joshua S Davis
Journal:  J Clin Microbiol       Date:  2012-04-04       Impact factor: 5.948

3.  Adverse outcomes among Aboriginal patients receiving peritoneal dialysis.

Authors:  Manish M Sood; Paul Komenda; Amy R Sood; Martina Reslerova; Mauro Verrelli; Chris Sathianathan; Loretta Eng; Amanda Eng; Claudio Rigatto
Journal:  CMAJ       Date:  2010-07-26       Impact factor: 8.262

4.  Peritonitis and exit site infections in First Nations patients on peritoneal dialysis.

Authors:  Ainslie Hildebrand; Paul Komenda; Lisa Miller; Claudio Rigatto; Mauro Verrelli; Amy R Sood; Chris Sathianathan; Martina Reslerova; Loretta Eng; Amanda Eng; Manish M Sood
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-19       Impact factor: 8.237

Review 5.  Community-associated methicillin-resistant Staphylococcus aureus infection: Literature review and clinical update.

Authors:  Kassandra Loewen; Yoko Schreiber; Mike Kirlew; Natalie Bocking; Len Kelly
Journal:  Can Fam Physician       Date:  2017-07       Impact factor: 3.275

6.  Is Streptococcus pyogenes resistant or susceptible to trimethoprim-sulfamethoxazole?

Authors:  Asha C Bowen; Rachael A Lilliebridge; Steven Y C Tong; Robert W Baird; Peter Ward; Malcolm I McDonald; Bart J Currie; Jonathan R Carapetis
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

Review 7.  Population-based epidemiology and microbiology of community-onset bloodstream infections.

Authors:  Kevin B Laupland; Deirdre L Church
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

8.  Virulence of endemic nonpigmented northern Australian Staphylococcus aureus clone (clonal complex 75, S. argenteus) is not augmented by staphyloxanthin.

Authors:  Steven Y C Tong; Batu K Sharma-Kuinkel; Joshua T Thaden; Adeline R Whitney; Soo-Jin Yang; Nagendra N Mishra; Thomas Rude; Rachael A Lilliebridge; Maria A Selim; Sun Hee Ahn; Deborah C Holt; Philip M Giffard; Arnold S Bayer; Frank R Deleo; Vance G Fowler
Journal:  J Infect Dis       Date:  2013-04-18       Impact factor: 5.226

9.  Community-associated methicillin-resistant Staphylococcus aureus in northwest Ontario: A five-year report of incidence and antibiotic resistance.

Authors:  Jill Muileboom; Marsha Hamilton; Karen Parent; Donna Makahnouk; Michael Kirlew; Raphael Saginur; Freda Lam; Len Kelly
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

10.  Phylogenetically distinct Staphylococcus aureus lineage prevalent among indigenous communities in northern Australia.

Authors:  Jacklyn W S Ng; Deborah C Holt; Rachael A Lilliebridge; Alex J Stephens; Flavia Huygens; Steven Y C Tong; Bart J Currie; Philip M Giffard
Journal:  J Clin Microbiol       Date:  2009-05-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.